

Precision targeting of MET in NSCLC: A multidisciplinary approach



Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

Expert MDT panel



Dr Christine Argento
Interventional pulmonologist
Johns Hopkins University
School of Medicine,
Baltimore, MD, USA



Dr Xiuning Le
Thoracic medical oncologist
University of Texas
MD Anderson Cancer Center,
Houston, TX



Prof. Albrecht Stenzinger
Molecular pathologist
University Hospital Heidelberg,
Heidelberg , Germany



Dr Sandra Cuellar
Clinical oncology pharmacist
University of Illinois Chicago,
Chicago, IL, USA



Ms Stephanie McDonald
Oncology nurse practitioner
Dana-Farber Cancer Institute,
Boston, MA, USA

Discussion 1

Targeting *MET*ex14 skipping mutations:
Patient identification through molecular analysis

Dr Xiuning Le

Thoracic medical oncologist



Dr Christine Argento

Interventional pulmonologist



Prof. Albrecht Stenzinger

Molecular pathologist



Clinical case – Elizabeth

Patient history

- Female
- 81 years old
- Never-smoker



Diagnosis

- **Chest X-ray/CT/PET scans:**
 - Left pleural effusion
 - Tumour: 4 cm diameter in left lower lobe
 - Liver metastasis: 3 cm nodule
 - Multiple hypermetabolic masses in the left lung and lymph nodes
 - Hypermetabolic activity in the right supraclavicular region
- **MRI:** No brain metastases
- **ECOG-PS at diagnosis:** 2
- **Liquid biopsy:**
 - Stage IV NSCLC (adenocarcinoma)

Biopsy and biomarkers

- **Liquid biopsy:**
 - No actionable oncogene driver mutations detected

Treatment options

Discussion 2

Managing *MET*ex14 skipping mutations: Clinical insights and strategies


Dr Xiuning Le

Thoracic medical oncologist



Dr Sandra Cuellar

Clinical oncology pharmacist



Ms Stephanie McDonald

Oncology nurse practitioner



Clinical case – Elizabeth

Patient history

- Female
- 81 years old
- Never-smoker



Diagnosis

- **Chest X-ray/CT/PET scans:**
 - Left pleural effusion
 - Tumour: 4 cm diameter in left lower lobe
 - Liver metastasis: 3 cm nodule
 - Multiple hypermetabolic masses in the left lung and lymph nodes
 - Hypermetabolic activity in the right supraclavicular region
- **MRI:** No brain metastases
- **ECOG-PS at diagnosis:** 2
- **Liquid biopsy:**
 - Stage IV NSCLC (adenocarcinoma)

Biopsy and biomarkers

- **Liquid biopsy:**
 - No actionable oncogene driver mutations detected

EBUS-FNA

DNA and RNA NGS

- **METex14 skipping mutation**

Treatment options

MET-TKIs (oral)

- Crizotinib¹
 - Capmatinib¹
 - Tepotinib¹
 - Savolitinib (China)²
- } NCCN

CT, computed tomography; EBUS-FNA, endobronchial ultrasound-guided fine-needle aspiration; ECOG-PS, Eastern Cooperative Oncology Group performance status; MRI, magnetic resonance imaging; NGS, next-generation sequencing; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer; PET, positron emission tomography; TKI, tyrosine kinase inhibitor.

1. NCCN. Non-small cell lung cancer. Version 10.2024 (accessed 27 September 2024); 2. Yu Y, et al. *Lancet Respir Med.* 2024:S2213-2600(24)00211-X.

Discussion 3

Metastatic challenges:
Exploring *MET* amplification in refractory disease

Dr Xiuning Le
Thoracic medical oncologist



Dr Christine Argento
Interventional pulmonologist



Prof. Albrecht Stenzinger
Molecular pathologist



Clinical case – Andrew

Patient history

- Male
- 77 years old
- Former-smoker



First-line treatment

- Osimertinib monotherapy
(2 years)



Disease progression



Treatment options (NCCN)



Diagnosis and biomarkers

- **Chest X-ray/CT:**
 - 5 cm opacity in right upper lung
 - Solitary 4.5 cm radiodense mass
- **EBUS-FNA:**
 - Cytology consistent with NSCLC
- **Surgical core biopsy:**
 - Infiltrative tumour
 - IHC indicates adenocarcinoma
- **NGS:**
 - *EGFR*ex19 deletion



Follow-up

- **Clinical assessment:**
 - Increased cough, dyspnoea, pain and weight loss
- **CT scan:**
 - >20% increase in lesion diameter

Discussion 4

Navigating resistance: MET-targeted treatment strategies for refractory NSCLC

Dr Xiuning Le
Thoracic medical oncologist



Dr Sandra Cuellar
Clinical oncology pharmacist



Ms Stephanie McDonald
Oncology nurse practitioner



Clinical case – Andrew

Patient history

- Male
- 77 years old
- Former-smoker



First-line treatment

- **Osimertinib monotherapy**
(2 years)



Disease progression

- Platinum-based chemotherapy considered if there are no targetable resistance mutations

Treatment options (NCCN)

EGFR/MET bi-specific Ab (IV)^{1,2}

- Amivantamab

Osimertinib + MET-TKI (oral)¹

- Crizotinib
- Capmatinib
- Tepotinib

Diagnosis and biomarkers

- **Chest X-ray/CT:**
 - 5 cm opacity in right upper lung
 - Solitary 4.5 cm radiodense mass
- **EBUS-FNA:**
 - Cytology consistent with NSCLC
- **Surgical core biopsy:**
 - Infiltrative tumour
 - IHC indicates adenocarcinoma
- **NGS:**
 - *EGFR*ex19 deletion

Follow-up

- **Clinical assessment:**
 - Increased cough, dyspnoea, pain and weight loss
- **CT scan:**
 - >20% increase in lesion diameter

EBUS-FNA

- **Histology:**
 - No small cell or squamous transformation
 - Confirmed adenocarcinoma

NGS

- ***MET* amplification:**
 - >10 copies

Ab, antibody; CT, computed tomography; EBUS-FNA, endobronchial ultrasound-guided fine-needle aspiration; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; IV, intravenous; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.

1. NCCN. Non-small cell lung cancer treatment guidelines. Version 10.2024 (accessed 27 September 2024); 2. US Food and Drug Administration. Amivantamab-vmjw prescribing information. 2024. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf (accessed 27 September 2024).